VIENNA--(BUSINESS WIRE)--Dec 7, 2025--

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67 th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

ROP-ET and BESREMI PASS

One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET),

See Full Page